Combining molecular patterns and clinical data for better immune checkpoint inhibitor prediction in metastatic urothelial carcinoma
The therapeutic landscape of advanced urothelial carcinoma (UC) is evolving, making the prediction of immune checkpoint inhibitor (ICI) therapy efficacy crucial. Standalone biomarkers offer limited predictive value, necessitating integrative approaches combining clinicopathological, laboratory, and...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
December 2025
|
| In: |
Cancer immunology immunotherapy
Year: 2025, Jahrgang: 74, Heft: 12, Pages: 1-16 |
| ISSN: | 1432-0851 |
| DOI: | 10.1007/s00262-025-04224-8 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1007/s00262-025-04224-8 |
| Verfasserangaben: | M. Váradi, O. Horváth, E. Soós, A. Csizmarik, B. Németh, B. Győrffy, I. Kenessey, H. Reis, F. Koll, C. Oláh, B. Hadaschik, U. Krafft, V. Grünwald, F. Mairinger, M. Wessolly, M.J. Hoffmann, C.M. Grunewald, G. Niegisch, C.L. Cotarelo, A. Maráz, L. Kuthi, A.M. Szász, Z. Herold, M. Posta, B. Bátai, P. Nyirády, T. Szarvas |
MARC
| LEADER | 00000naa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 195056519X | ||
| 003 | DE-627 | ||
| 005 | 20260129093901.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 260129s2025 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00262-025-04224-8 |2 doi | |
| 035 | |a (DE-627)195056519X | ||
| 035 | |a (DE-599)KXP195056519X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Váradi, Melinda |e VerfasserIn |0 (DE-588)1388303256 |0 (DE-627)1950565742 |4 aut | |
| 245 | 1 | 0 | |a Combining molecular patterns and clinical data for better immune checkpoint inhibitor prediction in metastatic urothelial carcinoma |c M. Váradi, O. Horváth, E. Soós, A. Csizmarik, B. Németh, B. Győrffy, I. Kenessey, H. Reis, F. Koll, C. Oláh, B. Hadaschik, U. Krafft, V. Grünwald, F. Mairinger, M. Wessolly, M.J. Hoffmann, C.M. Grunewald, G. Niegisch, C.L. Cotarelo, A. Maráz, L. Kuthi, A.M. Szász, Z. Herold, M. Posta, B. Bátai, P. Nyirády, T. Szarvas |
| 264 | 1 | |c December 2025 | |
| 300 | |b Diagramme | ||
| 300 | |a 16 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online veröffentlicht: 12. November 2025 | ||
| 500 | |a Gesehen am 29.01.2026 | ||
| 520 | |a The therapeutic landscape of advanced urothelial carcinoma (UC) is evolving, making the prediction of immune checkpoint inhibitor (ICI) therapy efficacy crucial. Standalone biomarkers offer limited predictive value, necessitating integrative approaches combining clinicopathological, laboratory, and molecular factors to enhance accuracy. This study aimed to evaluate clinical and molecular factors, including the real-life performance of PD-L1 IHC, to improve treatment outcome prediction in ICI-treated UC patients, ultimately developing a more precise therapy selection model. | ||
| 650 | 4 | |a Gene expression based markers | |
| 650 | 4 | |a Immune checkpoint inhibitors | |
| 650 | 4 | |a Molecular subtypes | |
| 650 | 4 | |a PD-L1 | |
| 650 | 4 | |a Urothelial carcinoma | |
| 700 | 1 | |a Horváth, O. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Soós, E. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Csizmarik, A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Németh, B. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Győrffy, B. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kenessey, I. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Reis, H. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Koll, F. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Oláh, C. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hadaschik, B. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Krafft, U. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Grünwald, V. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mairinger, F. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wessolly, M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hoffmann, M. J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Grunewald, C. M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Niegisch, G. |e VerfasserIn |4 aut | |
| 700 | 1 | |a López-Cotarelo Rodríguez-Noriega, Cristina |d 1970- |e VerfasserIn |0 (DE-588)121996662 |0 (DE-627)705730646 |0 (DE-576)29303799X |4 aut | |
| 700 | 1 | |a Maráz, A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kuthi, L. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Szász, A. M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Herold, Z. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Posta, M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bátai, B. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Nyirády, P. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Szarvas, T. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer immunology immunotherapy |d Berlin : Springer, 1976 |g 74(2025), 12 vom: Dez., Artikel-ID 370, Seite 1-16 |h Online-Ressource |w (DE-627)253390443 |w (DE-600)1458489-X |w (DE-576)072283475 |x 1432-0851 |7 nnas |a Combining molecular patterns and clinical data for better immune checkpoint inhibitor prediction in metastatic urothelial carcinoma |
| 773 | 1 | 8 | |g volume:74 |g year:2025 |g number:12 |g month:12 |g elocationid:370 |g pages:1-16 |g extent:16 |a Combining molecular patterns and clinical data for better immune checkpoint inhibitor prediction in metastatic urothelial carcinoma |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s00262-025-04224-8 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |7 0 |
| 951 | |a AR | ||
| 992 | |a 20260129 | ||
| 993 | |a Article | ||
| 994 | |a 2025 | ||
| 998 | |g 121996662 |a López-Cotarelo Rodríguez-Noriega, Cristina |m 121996662:López-Cotarelo Rodríguez-Noriega, Cristina |d 60000 |d 63400 |e 60000PL121996662 |e 63400PL121996662 |k 0/60000/ |k 1/60000/63400/ |p 19 | ||
| 999 | |a KXP-PPN195056519X |e 4864195722 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"title":[{"title":"Combining molecular patterns and clinical data for better immune checkpoint inhibitor prediction in metastatic urothelial carcinoma","title_sort":"Combining molecular patterns and clinical data for better immune checkpoint inhibitor prediction in metastatic urothelial carcinoma"}],"person":[{"role":"aut","given":"Melinda","display":"Váradi, Melinda","family":"Váradi"},{"display":"Horváth, O.","role":"aut","given":"O.","family":"Horváth"},{"display":"Soós, E.","role":"aut","given":"E.","family":"Soós"},{"given":"A.","role":"aut","display":"Csizmarik, A.","family":"Csizmarik"},{"family":"Németh","display":"Németh, B.","given":"B.","role":"aut"},{"display":"Győrffy, B.","role":"aut","given":"B.","family":"Győrffy"},{"display":"Kenessey, I.","role":"aut","given":"I.","family":"Kenessey"},{"display":"Reis, H.","role":"aut","given":"H.","family":"Reis"},{"display":"Koll, F.","role":"aut","given":"F.","family":"Koll"},{"display":"Oláh, C.","given":"C.","role":"aut","family":"Oláh"},{"family":"Hadaschik","display":"Hadaschik, B.","role":"aut","given":"B."},{"family":"Krafft","display":"Krafft, U.","role":"aut","given":"U."},{"family":"Grünwald","given":"V.","role":"aut","display":"Grünwald, V."},{"family":"Mairinger","given":"F.","role":"aut","display":"Mairinger, F."},{"given":"M.","role":"aut","display":"Wessolly, M.","family":"Wessolly"},{"family":"Hoffmann","role":"aut","given":"M. J.","display":"Hoffmann, M. J."},{"given":"C. M.","role":"aut","display":"Grunewald, C. M.","family":"Grunewald"},{"display":"Niegisch, G.","given":"G.","role":"aut","family":"Niegisch"},{"given":"Cristina","role":"aut","display":"López-Cotarelo Rodríguez-Noriega, Cristina","family":"López-Cotarelo Rodríguez-Noriega"},{"family":"Maráz","role":"aut","given":"A.","display":"Maráz, A."},{"family":"Kuthi","role":"aut","given":"L.","display":"Kuthi, L."},{"family":"Szász","given":"A. M.","role":"aut","display":"Szász, A. M."},{"family":"Herold","given":"Z.","role":"aut","display":"Herold, Z."},{"display":"Posta, M.","role":"aut","given":"M.","family":"Posta"},{"family":"Bátai","display":"Bátai, B.","role":"aut","given":"B."},{"display":"Nyirády, P.","role":"aut","given":"P.","family":"Nyirády"},{"given":"T.","role":"aut","display":"Szarvas, T.","family":"Szarvas"}],"name":{"displayForm":["M. Váradi, O. Horváth, E. Soós, A. Csizmarik, B. Németh, B. Győrffy, I. Kenessey, H. Reis, F. Koll, C. Oláh, B. Hadaschik, U. Krafft, V. Grünwald, F. Mairinger, M. Wessolly, M.J. Hoffmann, C.M. Grunewald, G. Niegisch, C.L. Cotarelo, A. Maráz, L. Kuthi, A.M. Szász, Z. Herold, M. Posta, B. Bátai, P. Nyirády, T. Szarvas"]},"relHost":[{"origin":[{"publisher":"Springer","dateIssuedDisp":"1976-","dateIssuedKey":"1976","publisherPlace":"Berlin ; Heidelberg"}],"recId":"253390443","type":{"media":"Online-Ressource","bibl":"periodical"},"titleAlt":[{"title":"CII"}],"disp":"Combining molecular patterns and clinical data for better immune checkpoint inhibitor prediction in metastatic urothelial carcinomaCancer immunology immunotherapy","id":{"zdb":["1458489-X"],"issn":["1432-0851"],"eki":["253390443"]},"physDesc":[{"extent":"Online-Ressource"}],"note":["Gesehen am 15.05.2024","Fortsetzung der Druck-Ausgabe","Ungezählte Beil. ab 52.2003: Supplement"],"pubHistory":["1.1976 -"],"title":[{"title_sort":"Cancer immunology immunotherapy","subtitle":"CII","title":"Cancer immunology immunotherapy"}],"part":{"extent":"16","pages":"1-16","issue":"12","text":"74(2025), 12 vom: Dez., Artikel-ID 370, Seite 1-16","year":"2025","volume":"74"},"language":["eng"]}],"note":["Online veröffentlicht: 12. November 2025","Gesehen am 29.01.2026"],"physDesc":[{"noteIll":"Diagramme","extent":"16 S."}],"id":{"doi":["10.1007/s00262-025-04224-8"],"eki":["195056519X"]},"origin":[{"dateIssuedDisp":"December 2025","dateIssuedKey":"2025"}],"recId":"195056519X","type":{"media":"Online-Ressource","bibl":"article-journal"}} | ||
| SRT | |a VARADIMELICOMBININGM2025 | ||